Recommendations on seasonal influenza vaccine ingredients

draft
European Medicines Agency (EMA) Published suggestions Seasonal Flu Vaccine Ingredients 2024/2025 season. They are based on the World Health Organization’s assessment (WHO) and approved by the Committee for Medicinal Products for Human Use (Human Health Management Plan) at the March 2024 meeting. emergency working group (ETF) EMA recommendations Transition from quadrivalent to trivalent vaccines Not included Component B/Yamagatano longer poses a significant threat to public health.

The European Medicines Agency recommends removing this strain from all live attenuated vaccines from the 2024/2025 season.

Furthermore, they recommend This strain should be removed from all live attenuated vaccines According to reports, starting from the 2024/2025 season european publishing house. The EMA noted that in order to guarantee supply for the next vaccination campaign, the transition to trivalent composition As with all other flu vaccines, you should To be completed by the 2025/2026 season.

In addition, it has released a series of strain recommendations for this year.manufacturer of Live attenuated vaccine or trivalent egg vaccine should include these Three virus strains 2024/2025 season: viruses similar to A/Victoria/4897/2022 (H1N1)pdm09; viruses similar to A/Thailand/8/2022 (H3N2); and viruses similar to B/Austria/1359417/2021 (B/Victoria lineage ) similar viruses.

EMA recommends that manufacturers of inactivated vaccines consider producing a quadrivalent vaccine containing two influenza B strains for the 2024/2025 season.

Likewise, the manufacturer trivalent cell vaccine should include these Three virus strains 2024/2025 Season: Viruses similar to A/Wisconsin/67/2022 (H1N1)pdm09; Viruses similar to A/Massachusetts/18/2022 (H3N2); Similar to B/Austria/1359417/2021 (B/Victoria lineage) Similar viruses.As far as the manufacturer is concerned inactivated vaccine You may consider producing one Quadrivalent vaccine containing two strains of influenza B virus 2024/2025 season. In this case, in addition to the above-mentioned strains, viruses similar to B/Phuket/3073/2013 (B/Yamagata lineage) are considered suitable.

EMA recalled that, Influenza viruses are constantly changing and evolving

. Therefore, it is necessary to regularly change the virus strains in influenza vaccines. necessary to maintain effectiveness vaccine. In addition, manufacturers must submit applications to change vaccine ingredients by June 17, 2024, the report said.